Get the Stockscreener App
60.62
3.55%
-2.23
After Hours:
60.62
Haemonetics Corp stock is traded at $60.62, with a volume of 761.02K.
It is down -3.55% in the last 24 hours and up +5.43% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$62.85
Open:
$62.37
24h Volume:
761.02K
Relative Volume:
0.91
Market Cap:
$2.82B
Revenue:
$1.35B
Net Income/Loss:
$163.34M
P/E Ratio:
18.50
EPS:
3.2763
Net Cash Flow:
$189.17M
1W Performance:
-6.26%
1M Performance:
+5.43%
6M Performance:
+13.35%
1Y Performance:
-11.24%
1-Day Range:
$59.83
$63.47
1-Week Range:
$59.83
$65.10
52-Week Range:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
60.62 | 2.92B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
110.25 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.78 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.97 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.63 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics price target lowered to $70 from $75 at Citi - TipRanks
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
Assessing Haemonetics (HAE) Valuation After Recent Share Price Pullback - Yahoo Finance
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack - Yahoo Finance
A Review of Q4 Earnings for Medical Devices & Supplies Specialty Stocks: Comparing Haemonetics (NYSE:HAE) to Its Competitors - Bitget
Haemonetics Wins FDA Nod For Persona PLUS Plasma Growth Opportunity - simplywall.st
Haemonetics Corporation $HAE Shares Sold by Fisher Asset Management LLC - MarketBeat
Haemonetics Repays $300 Million Convertible Senior Notes Due 2026 - marketscreener.com
William Blair Investment Management LLC Buys 57,332 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp repays outstanding 0.00% convertible senior notesSEC filing - marketscreener.com
Haemonetics repays $300 million convertible notes at maturity By Investing.com - Investing.com Canada
Haemonetics repays $300 million convertible notes at maturity - Investing.com
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure - TipRanks
Haemonetics repays $300M 0.00% convertible notes due 2026 in cash - TradingView
Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System - simplywall.st
3 Reasons HAE is Risky and 1 Stock to Buy Instead - Finviz
Haemonetics at Raymond James: Strategic Growth and Challenges - Investing.com Nigeria
Haemonetics at Raymond James: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Royce & Associates LP Sells 569,815 Shares of Haemonetics Corporation $HAE - MarketBeat
Vanguard Group Inc. Reduces Stock Position in Haemonetics Corporation $HAE - MarketBeat
Kestrel Investment Management Corp Purchases New Shares in Haemonetics Corporation $HAE - MarketBeat
Ameritas Investment Partners Inc. Has $636,000 Holdings in Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics (HAE) Offering A Compelling Entry Point After Prolonged Share Price Weakness - simplywall.st
Haemonetics Corporation $HAE Stake Lessened by Citigroup Inc. - MarketBeat
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
Fox Run Management L.L.C. Takes $1.36 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Completes Hemerus Medical Acquisition - Yahoo
Zacks Research Forecasts Increased Earnings for Haemonetics - MarketBeat
Therapeutic Apheresis Market to Reach US$ 6,009.58 Million - openPR.com
Haemonetics (HAE) Is Up 5.3% After FDA Clears NexSys PCS With Persona PLUS Technology - simplywall.st
Haemonetics receives FDA clearance for plasma collection system - Investing.com
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology - PR Newswire
Clark Estates Inc. NY Takes $2.24 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics receives FDA clearance for plasma collection system By Investing.com - Investing.com Canada
Haemonetics Stock After Earnings: Quiet Breakout or Value Trap? - AD HOC NEWS
Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference - PR Newswire
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc. - MarketBeat
ABN Amro Investment Solutions Buys Shares of 200,000 Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 - Finviz
Growth Recap: Will Haemonetics Corporation outperform its industry peersJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth - Yahoo Finance
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 21.7% - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc. - MarketBeat
Haemonetics Releases 2024-2025 Corporate Responsibility Report - The Globe and Mail
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):